key: cord-0864159-h5l7yp58 authors: Kawata, Keisuke; Nakabayashi, Masaki title: Determinants of COVID-19 vaccine preference: A survey study in Japan date: 2021-08-24 journal: SSM Popul Health DOI: 10.1016/j.ssmph.2021.100902 sha: 52e4c5b1086de838d1bc5f8ac7976a47a24f32e4 doc_id: 864159 cord_uid: h5l7yp58 OBJECTIVE: Vaccination is a critical measure for containing the COVID-19 pandemic. We survey the determinants that affect the preference for COVID-19 vaccines in Japan, a vaccine hesitant nation. SETTING AND DESIGN: We conducted a randomized conjoint analysis survey of the preference for vaccines on the Internet by recruiting a nonprobability sample of 15,000 Japanese adults. The survey assigned 5 choice tasks to the respondents. In each task, the respondents evaluated 2 hypothetical COVID-19 vaccines and were asked which they would choose. The vaccine attributes included efficacy, major and minor adverse side effects, country of vaccine development and clinical trial, and vaccine type. TREATMENT: The choice task asked the participants to select a vaccine from 2 hypothetical vaccines as an optional vaccine or select a vaccine as mandated one with a probability of 0.5 for each. RESULTS: Compared to China-developed vaccines, domestically developed or US-developed vaccines raised the choice probability by 37.3 and 27.4 percentage points, respectively. A domestic clinical trial increased the choice probability by 14.8, an increase in efficacy from 50% to 90% increased that by 18.0, and a decrease in the risk of severe adverse side effects from 1 per 10 thousand to 1 per 1 million increased that by 16.9 percentage points, respectively. The vaccine type was irrelevant. Making vaccination compulsory increased the choice probability of China- and Russia-developed vaccines by 0.6 and 0.4, high-risk vaccines by 0.5, and a modestly effective (70%) vaccine by 0.4 percentage points, respectively. General vaccination hesitancy, political positions, demographic characteristics, education, and income were irrelevant. CONCLUSIONS: A domestically developed vaccine with a domestic clinical trial could substantially increase the preference for the vaccine. Making vaccination compulsory could modestly reduce the penalty for a vaccine with adverse side effects, geopolitical, and efficacy concerns, possibly through mitigating free-riding concerns to achieve herd immunity. Hesitancy regarding vaccines is a factor that hinders the achievement of herd immunity, and the reason and background characteristics of such hesitancy could be multidimensional (MacDonald (2015) ; Seanehia et al. (2017) ; Anderson et al. (2020) ; Keske et al. (2020) ; Nio et al. (2021) ; and Saied et al. (2021) ). Such hesitancy is a critical issue amid the COVID-19 pandemic with possible adverse side effects (Malik et al. (2020) ; Bell et al. Latkin et al. (2021) ; Mercadante and Law (2020) ; Ruiz and Bell (2021) ; Schoch-Spana et al. (2020); Troiano and Nardi (2021) ; Wong et al. (2021) ) along with the pecuniary costs of vaccination (Garca and Cerda (2020)). If we believe that vaccination could be effective in containing the pandemic despite the remaining technical uncertainty, then we must find a way to persuade people to get vaccinated. One possible approach is to identify peoples concerns regarding the entire process of development, clinical trials, and provisioning and address the issues as attempted by Gagneux-Brunon et al. (2021) . Among the possible settings used to measure stated preferences, randomized conjoint experiments (Hainmueller et al. (2014) and Hainmueller et al. (2015) ) in which vaccination attributes are randomly combined are effective in identifying the aspects people like and dislike. Such studies were implemented in China prior to the COVID-19 pandemic (Sun et al. (2020) ); in addition, to achieve better vaccination against COVID-19, such studies were conducted in the US (Kreps et al. (2020) ; Motta (2021) ; and Kaplan and Milstein (2021) ) and France (Schwarzinger et al. (2021) ). These studies report that efficacy has a positive impact while the side effect risk has a negative impact on hypothetical vaccine choice. Japan is not an exception to vaccination hesitancy (de Figueiredo et al. (2020) ). Furthermore, as of April, 2021, Japan does not have any vaccination production capacity. Thus, we implemented a randomized conjoint experiment involving 15,000 respondents to identify the factors associated with a more acceptable hypothetical vaccine. Additionally, an ultimate means to extend coverage of vaccination is to make it compulsory. Compulsory vaccination removes the possibility of free-riding in building herd immunity and hence might help, for instance, a risky vaccine prevail. Therefore, in our conjoint experiment, we randomly assigned one of two scenarios to the respondents and analyzed whether these scenarios resulted in different outcomes. We conducted an online survey in March, 2021 to measure individual valuations of hypothetical COVID-19 vaccines. The Ethical Review Board of the Institute of Social Science, The University of Tokyo approved this 1 J o u r n a l P r e -p r o o f study. The survey format was provided by Rakuten Insight 1 . Each question was assigned based on a previous question, and the respondents were not allowed to return to a previous question once they responded to or skipped the question. Each respondent was asked which of two hypothetical vaccines she/he would prefer. Randomized conjoint analysis originates from market research and has recently been applied to public health, including research aiming to identify the factors that affect attitudes toward COVID-19 vaccination in the US (Kreps et al. (2020) and Motta (2021) ). Our aim is to identify the type of vaccines that would be more likely to be accepted if people have to get vaccinated. The supply bottleneck of COVID-19 vaccines is currently an issue. However, eventually, the supply will meet the demand. Then, a critical issue becomes the vaccine hesitancy of the public. At this stage, the government must persuade the public to get vaccinated. The cost of the implementation of such a policy could be reduced if the authorities knew the types of vaccines that are less disliked. To address this issue, we do not allow the respondents to opt out of vaccination. The respondents are asked which of two hypothetical vaccines they prefer when they do not have a choice to opt out of vaccination. Before introducing the hypothetical vaccines, we randomly presented two different scenarios to the respondents. One scenario asked the respondents which vaccine she/he preferred for herself/himself. The other scenario asked the respondents which vaccine should be selected if the government made vaccination compulsory. A theoretically possible difference between these scenarios is that the former self-choice scenario might include free-rider problem effects. Not all individuals need to get vaccinated to achieve herd immunity. For example, if most people other than one individual get vaccinated, the unvaccinated person would be protected by the herd immunity built by the efforts of other people and might have incentive to avoid riskier vaccinations. The latter scenario of compulsory vaccination reduces such free-riding concerns. In this survey, the respondents were informed of the vaccines being supplied and under development. Each hypothetical vaccine profile consisted of the following 6 categories: a) risk of severe adverse side effects resulting in hospitalization or death, b) risk of mild adverse side effects resulting in flu-like symptoms, c) efficacy in protecting against severe symptoms, d) type of vaccine, namely, messenger RNA, inactivated virus, or weakened virus, e) country of development (Japan, US, China, UK, or Russia), and f) country of clinical trial (in Japan or not in Japan). Notably, our aim is to identify the respondents' usual preference for vaccines given their knowledge; therefore, we did not provide additional information regarding the vaccine types. The attributes are summarized in Table 1 . For each category, one attribute level was randomly drawn to characterize a hypothetical vaccine. Two such hypothetical vaccines were shown to the respondents, who were then asked to make a choice. We did not allow the respondents to opt out; therefore, between two levels of an attribute, the relatively disliked level was selected with a probability less than 0.5, and the preferred level was selected with a probability greater than 0.5. Each respondent participated in 5 selection tasks, resulting in 10 outcomes, including the chosen vaccine and unchosen vaccine in each task. In summary, we collected 10 (outcomes) × 15,000 respondents = 150,000 samples. While our sample has a slightly denser distribution of the high-income level (higher than JPY10 million), the overall distribution of our survey does not greatly differ from that of the MHLW survey. Let Y ij (a, d) be a potential outcome indicator, which takes = 1 if respondent i chooses alternative j and = 0 otherwise. a = [a j , a −j ] is a set of two vectors of attributes, where a j and a −j are attribute vectors of alternative vaccines j and −j shown to respondent i, respectively. d is an indicator of the scenario, which takes = 1 if the scenario shown to the respondent assumed that the government was to make vaccination compulsory and = 0 if the scenario asked the respondent to choose a hypothetical vaccine for themselves. Let A ij be a hypothetical vaccine selected by respondent i, and let D i be a scenario shown to respondent i. Because observed A ij and D i are randomized, the average marginal potential outcome is identified as follows: 3 Description of the survey: https://www.mhlw.go.jp/toukei/list/20-21.html Last accessed on July 5, 2021. ( Regarding intervention of whether to make vaccination mandatory, our estimate of interest is obtained as follows: ( In our estimation, we focus on the marginal value given a level of attribute l as follows: (3) where a −lj denotes a vector created by removing element l from a j , and f denotes the joint density function. J o u r n a l P r e -p r o o f To estimate conditional means E Y obs ij |A ij = a, D i = d in equation (1), the augmented inverse propensity score weight is employed. The conditional mean is defined as follows: Thus we follow the estimation process such that: 1. µ d (a) may essentially be estimated by any high-quality estimation method. In this case, 20-fold crossfitted highly adaptive LASSO (Tibshirani (1996) and Benkeser and van der Laan (2016)) is employed. e (a) is fixed as 0.5 in our experimental design since we did not allow the respondents to opt out when choosing between two hypothetical vaccines. The highly adaptive LASSO is implemented according to hal2009 (Hejazi et al. (2020) ) with the default hyperparameter values. 2. We calculate the estimated score functionM ij (d) =μ is the average potential outcome, which is estimated by excluding the fold that includes respondent i. ij (d) on A ij to estimate a−j E [Y ij (d, a j , a −j )] × f (a −j ). The average marginal potential outcome, which is defined by equation (3), is presented in Figure 1 , which reports the results of the scenario of self-choice without considering a government ordinance to make vaccination compulsory. J o u r n a l P r e -p r o o f Notes: Confidence interval is 95%. The country of development is the factor most strongly associated with a preference for a vaccine. A change from a China-developed vaccine to a Russia-developed increased the respondents preference by 41.7% (from 0.292 to 0.413), a change to a UK-developed vaccine increased the choice probability by 93.1% (to 0.564), a change to a US-developed vaccine increased the choice probability by 93.8% (to 0.566), and a change to a Japandeveloped vaccine increased the choice probability by 127.7% (to 0.665). In our setting, the reference point is 0.5 such that while both China-produced and Russia-produced vaccines were penalized, the penalty was much greater for the China-produced vaccine. A similar penalty on China-produced vaccines has been reported in the US (Kreps et al. (2020) and Kreps and Kriner (2021) ) and France (Schwarzinger et al. (2021) ). Similar to the 8 J o u r n a l P r e -p r o o f finding of Kreps et al. (2020) and Kreps and Kriner (2021) of a geopolitical penalty on China-produced vaccines, Japanese respondents penalized China the most, followed by Russia. The second largest impacts were the location of the clinical trials and risk of severe side effects. The preference for a hypothetical vaccine increased by 34.7% (from 0.426 to 0.574) if the clinical trials were conducted in Japan than in other countries, and the probability of preferring a vaccine increased by 40.7% (from 0.415 to 0.584) if the probability of severe adverse side effects decreased from 1 per ten thousand to 1 per 1 million. Third, efficacy had modest impacts. An increase in efficacy in preventing severe symptoms, such as hospitalization or death, by 50% to 70% raised the choice probability by 24.3% (from 0.407 to 0.506), and an efficacy of 90% raised the choice probability by 44.2% (to 0.587). Fourth, the vaccine type did not affect the choice probability of a vaccine. Our randomized conjoint design includes both efficacy and side effect risk. The respondents chose a hypothetical vaccine between two vaccines given the efficacy and side effect risk specified by hypothetical vaccine attributes. Hence, the two following possibilities could explain the irrelevance of the vaccine types we observed. 1. The respondents' concerns regarding the probabilistic factors of vaccine types all depend on the efficacy and side effect risk. Therefore, our conjoint design including efficacy and side effect risk as attributes resolves all the risk relevant to the respondents such that the vaccine types conditional on the specified efficacy and side effects were irrelevant to the respondents. 2. While the respondents were subjectively concerned about probabilistic factors other than the specified efficacy and side effect risk, they did not have enough knowledge to differentiate the vaccine types such that the vaccine types were not associated with the probability of a hypothetical vaccine being chosen. We cannot identify which of the two possibilities is more likely by our design. As a robustness check, we estimated the average marginal component effects among the respondents aged 60 or older, those with high school or less as the highest degree of education, and those who resided outside of a metropolitan area (Greater Tokyo: Tokyo, Saitama, Chiba, and Kanagawa; Greater Nagoya: Gifu, Aichi, and Mie; and Greater Osaka: Kyoto, Osaka, Gyogo, and Nara), as shown in the appendix. The findings were qualitatively the same as those of the entire sample. J o u r n a l P r e -p r o o f Finally, we estimate equation (2) such that The results are presented in Figure 2 . Notes: Confidence interval is 95%. As indicated in equation (5), Figure 2 shows the difference in choosing a hypothetical vaccine between the cases when it was optional and when it was government mandated by subtracting the former's value from the latter's value. While the effects of making the vaccine compulsory are generally modest, the penalty on a Chinaproduced vaccine decreased by 6%, the penalty on a Russia-produced vaccine decreased by 4%, and the penalty on a high-risk vaccine (1 per 10 thousand) decreased by 5%. Additionally, the support for a hypothetical vaccine with modest efficacy (70%) increased by 4%. Figure 2 shows the difference between optional vaccination and mandatory vaccination. Thus, negative or slight effects do not indicate negative or irrelevant support for a vaccine. Instead, such an effect indicates whether the preference for a vaccine increases if it was mandated. For instance, a rise in support for a hypothetical vaccine with 70% efficacy does not indicate that the vaccine was preferred over the other vaccine but that it would have been more preferred if it was mandated. The potential margins of the increase due to compulsory vaccination are larger for disliked vaccines. In summary, a rise in preference due to mandatory vaccination captures a rise in preference because it is impossible to avoid less preferred vaccines; thus, more people accept the vaccine. One possible interpretation is that people tend to accept less effective or riskier vaccines if vaccination is mandatory because mandatory vaccination eliminates free-riding concerns. Notes: Confidence interval is 95%. J o u r n a l P r e -p r o o f The results indicate that making vaccination compulsory increases the choice probability of highly risky China-, Russia-, and UK-produced vaccines by 1% but does not affect Japan-or US-produced vaccines, less risky vaccines, and the most effective vaccines. We screened the interactions between the vaccine attributes and background characteristics, including previous COVID-19 infection experience, general attitudes toward vaccination, past vaccination or vaccination refusal experience, trust in doctors' advice, trust in the government's vaccine licensing, education, income, and political positions, as indicated in Table 2 , but these characteristics did not have substantial impacts on the preference for hypothetical vaccines. The irrelevance of past vaccination experience is consistent with the results reported by Kreps and Kriner (2021) . Therefore, we conclude that some attributes of vaccines impact vaccination preferences across diverse background characteristics. As noted by Matta (2020) , better scientific communication between the public and authorities is effective as a better approach to containing the pandemic. Better communication could be achieved by either enhancing public knowledge or deepening the authorities' understanding of the public's fear. Regarding this issue, Nio et al. (2021) and Saied et al. (2021) specified the factors that could render people hesitant about vaccination. Given this tendency, if the tendency is within the authorities' discretion, they could better address the issue. We attempted to provide such information to relevant policy makers. Domestic production and domestic clinical trials are strongly preferred by Japanese adults. However, such vaccines cannot be expected in the very near future. The US-produced vaccines are preferred and are expected to be preferred by participants. Regarding compulsory vaccination, riskier, modestly effective, China-produced and Russia-produced vaccines have increased support. If Japan cannot obtain a sufficient quantity of US-produced vaccines and must deploy riskier, modestly effective, China-produced or Russia-produced vaccines as substitutes, then compulsory vaccination could be an effective way to reduce free-riding concerns. If the government should deploy riskier vaccines, then compulsory vaccination might help. The channel of externality, which reflects positive spillover effects such that people might seek to free ride on others' vaccination, was asymmetric. If the reduction in the externality concerns channel was symmetric to both removing negative externality (free-riding concerns) and materializing positive externality ("win-win" scenario between vaccine supporters and the vaccine hesitant), then legislation for compulsory vaccination would have increased support for the most effective vaccines (90%), which was not observed in our experiment. These 12 J o u r n a l P r e -p r o o f findings suggest that the public primarily expects the authorities to curb free-riding. Regarding the vaccine hesitant who might want to be protected by herd immunity but want to avoid vaccination, the public wants the government to force the vaccine hesitant to get vaccinated. The primary limitations of our research are related to the irrelevance of possible learning through vaccination experience and irrelevance of the vaccine types. As described in Kreps and Kriner (2021) , past vaccination experiences were not associated with the choice of hypothetical vaccines. While we cannot identify the possible reasons, this finding might indicate that vaccine preference does not necessarily evolve over vaccination experience. If so, authorities should not wait to provide appropriate vaccines until the public learns. Although active instructions and suggestions seem to be necessary, the issue is beyond our design, and inquiry regarding this issue is left for future research. Additionally, while we did not observe an association between the vaccine types and the likelihood of choice, we cannot identify whether this finding was because the respondents' were only concerned about efficacy and side effect risk, rendering the vaccine type irrelevant, or because the respondents did not have enough knowledge to differentiate the vaccines even though they cared about factors other than efficacy and side effect risk. Knowing which explanation is correct could be helpful for the authorities to convey appropriate vaccines. However, this issue is left for future research. Validating vignette and conjoint survey experiments against real-world behavior Causal inference in conjoint analysis: Understanding multidimensional choices via stated preference experiments hal9001': Scalable highly adaptive lasso regression in 'r' Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance Fearing the disease or the vaccine: The case of covid-19 Influenza vaccination among infection control teams: A EUCIC survey prior to COVID-19 pandemic Factors influencing covid-19 vaccine acceptance across subgroups in the united states: Evidence from a conjoint experiment Factors associated with us adults' likelihood of accepting covid-19 vaccination Measuring vaccine hesitancy: The development of a survey tool Trust in a COVID-19 vaccine in the U.S.: A social-ecological perspective Vaccine hesitancy: Definition, scope and determinants Determinants of COVID-19 vaccine acceptance in the US Science communication as a preventative tool in the covid19 pandemic Will they, or Won't they? Examining patients' vaccine intention for flu and COVID-19 using the Health Belief Model. Research in Social and Administrative Pharmacy Can a covid-19 vaccine live up to americans expectations? a conjoint analysis of how vaccine characteristics influence vaccination intentions Trajectories of COVID-19 vaccine intentions among U.S. adults: The role of race and ethnicity. SSM -Population Health 15, 100824 Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey Vaccine hesitancy: Beliefs and barriers associated with covid-19 vaccination among egyptian medical students The publics role in COVID-19 vaccination: Human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics Quantifying population preferences around vaccination against severe but rare diseases: A conjoint analysis among French university students A conjoint analysis of stated vaccine preferences in Regression shrinkage and selection via the lasso Vaccine hesitancy in the era of COVID-19 The french public's attitudes to a future covid-19 vaccine: The politicization of a public health issue Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong • As a treatment, we randomly assigned voluntary and compulsory vaccination scenarios We conducted this survey online. In addition to concerns, educational background, Internet literacy that might depend on age, and urbanization might have affected the results. Thus, we calculated the main result (Figure 1) in a restricted sample such that the respondents' highest degree was high school or less, the respondents' residence was outside of metropolitan regions, i.e., greater Tokyo (Tokyo, Saitama, Chiba, and Kanagawa prefectures), greater Nagoya (Gifu, Aichi, and Mie prefectures), and greater Osaka (Kyoto, Osaka, Nara, and Hyogo prefectures), and the respondents were aged 60 or older. As shown in Figure A1 , China-developed vaccines are less preferred then Japan-developed vaccines by 64% (from 0.689 to 0.247), and Russia-developed vaccines are less preferred by 46.5% (from 0.689 to 0.368). Clinical trials conducted in Japan increased the vaccine preference more by 30% (from 0.417 to 0.587). Severe side effects in 1 per million increased the preference for the